At an oral explanation, the Applicant presented additional subgroup analyses in support of the amended indication, restricted to patients at high risk of recurrence (node positive and within 1 year of completion of prior adjuvant trastuzumab based therapy). The estimated absolute iDFS treatment differences were 3.1% (95% CI: 0.3, 5.8) and 3.7% (95% CI: 0.4, 7.0) at the 2-year and 5-year analysis timepoints, respectively.